A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma

Trial Profile

A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Everolimus (Primary) ; Sonidegib (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Nov 2014 Planned primary completion date changed from 1 Dec 2020 to 1 Nov 2020, as reported by ClinicalTrials.gov.
    • 10 Nov 2014 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
    • 23 Oct 2014 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2020, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top